Patient with papillary thyroid cancer will present as → a 32-year-old female presents with a painless neck lump noticed two months ago. Physical exam reveals a 2 cm firm thyroid nodule in the right lobe without lymphadenopathy. Thyroid function tests are normal. Ultrasound shows a hypoechoic nodule with microcalcifications, and FNA confirms papillary thyroid carcinoma. The patient undergoes total thyroidectomy, followed by consideration of radioactive iodine ablation. She is started on levothyroxine with TSH suppression therapy. Long-term monitoring includes thyroglobulin levels, neck ultrasounds, and whole-body scans to check for recurrence.
Patient with adrenal carcinoma will present as → a 47-year-old woman presents with a 3-month history of weight gain, facial rounding, and muscle weakness. She also reports easy bruising and new-onset hypertension. Physical examination reveals central obesity, facial plethora, and wide purple abdominal striae. Laboratory tests show elevated serum cortisol and suppressed ACTH levels. A CT scan of the abdomen reveals a 6 cm adrenal mass with irregular borders and calcifications. Further workup, including a dexamethasone suppression test, confirms adrenal carcinoma with hypercortisolism. The patient undergoes adrenalectomy, and adjuvant mitotane therapy is initiated for residual disease.
Patient with parathyroid carcinoma will present as → a 50-year-old man presents with severe fatigue, constipation, and recurrent kidney stones. He also reports generalized bone pain over the past several months. Laboratory findings show a calcium level of 14.2 mg/dL, elevated parathyroid hormone (PTH), and low phosphate levels. A neck ultrasound identifies a 3.5 cm parathyroid mass with irregular margins. Fine-needle aspiration confirms parathyroid carcinoma. The patient undergoes en bloc resection of the affected parathyroid gland and adjacent tissues. Postoperatively, calcium levels normalize, and the patient is advised on close follow-up to monitor for recurrence.
Patient with pancreatic neuroendocrine tumor (PNET) will present as → a 42-year-old man presents with episodic confusion, sweating, and palpitations that resolve with eating. He has gained 10 pounds over the last 3 months due to frequent snacking to prevent symptoms. Laboratory evaluation reveals fasting hypoglycemia with an insulin level of 10 μU/mL (normal < 3) and a C-peptide level of 2.8 ng/mL (normal < 0.6). A CT scan shows a 2 cm pancreatic mass in the tail of the pancreas. Endoscopic ultrasound-guided fine-needle aspiration confirms an insulinoma, a functional pancreatic neuroendocrine tumor (PNET). The patient undergoes a laparoscopic distal pancreatectomy, and symptoms resolve postoperatively.
Primary Endocrine Malignancy refers to cancers arising from hormone-producing endocrine glands (thyroid, parathyroid, adrenal glands, or pancreas), often leading to hormonal overproduction and mass effects
The most common types include:
- Thyroid cancer (e.g., papillary (80%), follicular, medullary, anaplastic)
- Adrenal carcinoma
- Parathyroid carcinoma
- Pancreatic neuroendocrine tumors (PNETs)
- Pituitary carcinoma (rare)
Risk factors:
- Radiation exposure (e.g., childhood head and neck radiation)
- Family history of endocrine neoplasia (e.g., MEN syndromes)
- Genetic mutations (e.g., RET proto-oncogene in medullary thyroid carcinoma)
Symptoms depend on the gland and hormone secreted:
- Thyroid cancer: Neck mass, dysphagia, hoarseness, or thyrotoxicosis (in functional cancers)
- Adrenal malignancies: Hypercortisolism (Cushing’s syndrome), hyperaldosteronism (Conn’s syndrome), or catecholamine excess (pheochromocytoma)
- Parathyroid carcinoma: Severe hypercalcemia, nephrolithiasis, or bone pain
- Pancreatic neuroendocrine tumors: Symptoms of hormone overproduction, such as hypoglycemia (insulinoma) or peptic ulcers (gastrinoma)
The diagnosis of primary endocrine malignancies depends on the specific organ involved and appropriate testing
- Thyroid malignancies:
- Ultrasound is the best initial screen, followed by a thyroid uptake scan. Usually, normal thyroid function
- Microcalcifications, hypoechogenicity, a solid cold nodule, irregular nodule margins, chaotic intranodular vasculature, and a nodule that is more tall than wide
- Fine-needle aspiration (FNA) biopsy – Diagnostic test of choice
- Thyroglobulin levels – Marker for papillary/follicular thyroid cancer recurrence
- Ultrasound is the best initial screen, followed by a thyroid uptake scan. Usually, normal thyroid function
- Adrenal carcinoma:
- CT or MRI of the adrenal glands – Assess for size, irregular margins, and metastases
- Hormonal evaluation for cortisol, aldosterone, androgens
- Pancreatic neuroendocrine tumors:
- Endoscopic ultrasound (EUS) and biopsy
- Hormonal assays for insulin, gastrin, or glucagon based on symptoms
- Parathyroid carcinoma:
- Serum calcium and parathyroid hormone (PTH) – Elevated in hyperparathyroidism
- Sestamibi scan or ultrasound for localization
Treatment of primary endocrine malignancies focuses on surgical resection and adjuvant therapies tailored to the tumor type
- Thyroid cancer:
- Surgical resection (lobectomy or total thyroidectomy) is first-line
- Radioactive iodine (RAI) therapy for papillary/follicular types
- External beam radiation for anaplastic or advanced cases
- Long-term thyroid hormone suppression therapy to lower TSH and prevent recurrence
- Adrenal carcinoma:
- Surgical removal of the adrenal gland
- Mitotane (adrenolytic drug) for unresectable or metastatic cases
- Pancreatic neuroendocrine tumors:
- Surgical excision if localized
- Somatostatin analogs (e.g., octreotide) for symptom control
- Targeted therapy (e.g., everolimus) or chemotherapy for advanced cases
- Parathyroid carcinoma:
- En bloc resection of the affected parathyroid gland
- Management of hypercalcemia with IV fluids, bisphosphonates, or calcimimetics
- Adjuvant care:
- Surveillance imaging and labs to monitor for recurrence
- Genetic counseling for hereditary cases (e.g., MEN syndromes)
Preventing primary endocrine malignancies involves addressing risk factors and early detection
- Minimizing radiation exposure, especially in children
- Screening for genetic mutations (e.g., RET, MEN1, or MEN2) in high-risk individuals
- Regular neck exams and thyroid ultrasound for those with family history
- Monitoring for symptoms of hormonal excess in endocrine tumor syndromes
Flashcards ready when you areYou have opened several Quizlet sets recently. Loading this one only when needed helps prevent a temporary Quizlet limit.
Question 1 |
A 50-year-old woman presents with a neck mass and fatigue. She has a history of iodine deficiency and lives in a region with endemic goiter. Examination reveals a hard, irregular thyroid nodule. Fine-needle aspiration confirms the diagnosis of papillary thyroid carcinoma. Which of the following is the strongest risk factor for developing this condition?
RET proto-oncogene mutation Hint: This is associated with medullary thyroid carcinoma, not papillary thyroid carcinoma. | |
Iodine deficiency Hint: This is a risk factor for follicular thyroid carcinoma rather than papillary thyroid carcinoma. | |
Childhood radiation exposure | |
Family history of medullary thyroid carcinoma Hint: This is specific to medullary thyroid carcinoma, often linked to MEN2 syndromes. | |
Hashimoto's thyroiditis Hint: While it may increase the risk of thyroid lymphoma, it is not a strong risk factor for papillary thyroid carcinoma. |
Question 1 Explanation:
Childhood radiation exposure is the most significant risk factor for developing papillary thyroid carcinoma, the most common type of thyroid cancer. Exposure to ionizing radiation, especially during childhood, increases the likelihood of DNA mutations in thyroid cells, leading to malignancy. Papillary thyroid carcinoma accounts for about 85% of all thyroid cancers and has an excellent prognosis with early treatment. Other risk factors, such as iodine deficiency, are more closely associated with follicular thyroid carcinoma.
Question 2 |
A 32-year-old woman presents with a thyroid nodule detected on routine examination. She reports no symptoms but has a family history of medullary thyroid carcinoma. Serum calcitonin levels are elevated, and genetic testing confirms a RET proto-oncogene mutation. What is the next best step in diagnosing this patient’s thyroid nodule?
Thyroid ultrasound Hint: While useful for assessing nodule size and characteristics, ultrasound cannot confirm malignancy. | |
Fine-needle aspiration (FNA) biopsy | |
Measurement of serum thyroglobulin Hint: This is used to monitor differentiated thyroid cancers, not MTC. | |
Radioactive iodine uptake scan Hint: This test is not effective for MTC, as MTC cells do not take up iodine. | |
PET-CT scan Hint: This is typically reserved for metastatic disease evaluation and is not a first-line diagnostic tool for thyroid nodules. |
Question 2 Explanation:
Fine-needle aspiration (FNA) biopsy is the gold standard for evaluating thyroid nodules to confirm malignancy, including medullary thyroid carcinoma (MTC). In patients with elevated calcitonin and a RET mutation, FNA provides cytological evidence of C-cell proliferation or malignancy. Calcitonin is a sensitive marker for MTC, but biopsy is necessary to establish a definitive diagnosis and guide management.
Question 3 |
A 48-year-old woman presents with severe fatigue, bone pain, and recurrent kidney stones. Lab results reveal a calcium level of 13.5 mg/dL, elevated parathyroid hormone (PTH) levels, and imaging identifies a suspicious parathyroid mass. Fine-needle aspiration confirms parathyroid carcinoma. What is the most appropriate initial treatment for this condition?
Bisphosphonates and observation Hint: Bisphosphonates can help lower serum calcium levels but do not treat the underlying malignancy and are not a definitive therapy. | |
Total parathyroidectomy with en bloc resection | |
Radiation therapy Hint: Parathyroid carcinoma is typically resistant to radiation, making it an ineffective first-line treatment. | |
Chemotherapy with cisplatin Hint: Chemotherapy is not effective for parathyroid carcinoma and is not part of standard management. | |
Partial parathyroidectomy Hint: Incomplete resection is associated with a high risk of local recurrence and persistent hypercalcemia, making this approach inadequate. |
Question 3 Explanation:
The most effective treatment for parathyroid carcinoma is total parathyroidectomy with en bloc resection of the tumor and any surrounding involved tissues. This approach minimizes the risk of recurrence, which is common in parathyroid carcinoma. Surgery is the only curative treatment, and complete tumor excision is critical as these tumors are often resistant to adjunct therapies like radiation and chemotherapy. Elevated calcium and PTH levels typically normalize following successful surgery.
There are 3 questions to complete.
|
List |
References: UpToDate